Highlights from the breakout session: vasculitis in paediatric rheumatology
Authors' conclusion
The workshop underscored the importance of continued research and tailored therapeutic strategies to improve outcomes in pediatric vasculitis, paving the way for advancements in diagnosis, management, and understanding of these complex diseases.
Study context
- Population
- Paediatric vasculitis, including IgA Vasculitis (IgAV), Kawasaki Disease (KD) and monogenic vasculitides (e.g. deficiency of ADA2)
Methodological detailsbreakout session highlights, 21st International Vasculitis Workshop, 21st International Vasculitis Workshop, Barcelona, Spain, April 7 to 10, 2024
- Breakout session highlights
- 21st International Vasculitis Workshop
- 21st International Vasculitis Workshop, Barcelona, Spain, April 7 to 10, 2024
Main finding
As reported in the abstract
- Ankara 2008 criteria for IgAV (endorsed by EULAR and PReS) in adults: high sensitivity, specificity needs further refinement
- Genetic associations (Human Leukocyte Antigen (HLA) polymorphisms in IgAV) and biomarkers (S100A8/A9, HMGB1, RAGE) presented
- KD: novel anti-apolipoprotein A-2 antibodies showed promise in reducing coronary arteritis
- Monogenic vasculitides (e.g. deficiency of ADA2) addressed with new consensus-driven recommendations
Original publication
Highlights from the breakout session: vasculitis in paediatric rheumatology. Rheumatology (Oxford). Published 12 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →